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BACKGROUND: A long-standing hypothesis is that oxidative stress is a risk factor for cancer. Support for this hypothesis comes from
observations of higher levels of oxidative damage in the DNA of WBC of cancer patients compared with healthy controls.
METHODS: Two generally overlooked types of DNA damage, the formamide modification and the thymine glycol modification, both
derived from pyrimidine bases, were assayed as markers of oxidative stress. Damage levels were measured in the DNA of WBC of
ovarian cancer patients and of healthy controls.
RESULTS: The levels of both modifications were higher in ovarian cancer patients than in healthy controls although in the case of the
formamide modification age could not be ruled out as a factor.
CONCLUSION: Our results in combination with other published measurements of oxidative DNA damage support the hypothesis that
oxidative damage, on average, is higher in WBC of cancer patients than in healthy controls.
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Oxidative stress in cells arises from an imbalance between pro- and
antioxidants, in favour of the former. All cells exhibit a measurable
level of oxidative DNA damage (Ames et al, 1992). Individuals
exhibiting a higher level of oxidatively induced DNA damage than
healthy controls may have an inherent deficiency either in DNA
repair capacity or in protection against oxidative stress. Either
deficiency implies a higher mutation rate and consequently a
greater risk of cancer. Experimental data suggest that oxidatively
induced DNA damage is, in fact, elevated in cancer patients.
Our study was based on measurements of pyrimidine base
damage produced by reactive oxygen species (ROS) in white blood
cells (WBC) from human blood samples. The base modifications of
interest were the thymine glycol modification of thymine and the
formamide modification derived from the breakdown of pyrimi-
dine bases (Bailey et al, 2006; Greene et al, 2007). These
modifications were examined in two aspects: (1) Production
in vitro by radiation, both ionising and UVC; (2) The relationship
of DNA base damage to cancer, particularly ovarian cancer.
MATERIALS AND METHODS
Blood samples were obtained from ovarian cancer patients and
from healthy volunteers. The case group was composed of
successive patients admitted to the service having been diagnosed
with stage 3 ovarian cancer. The control group, composed of
healthy adult women, was randomly recruited from volunteer
donors. The samples from patients were obtained after surgery and
diagnosis, but before chemotherapy. Samples from patients and
volunteer donors were obtained under Institute Review Board-
approved protocols. Patients and volunteers were asked to fill out a
questionnaire regarding medical and family histories and lifestyle.
Information with respect to age proved to be especially important
for this study.
Buffy coat was isolated by centrifugation from fresh blood
collected with EDTA as anticoagulant. The cells were washed and
resuspended in either PBS (Dulbecco), or in plasma from the
original blood sample. DNA was extracted using a kit (ZeptoMetrix
Corp., Buffalo, NY, USA) that is based on the chaotropic extraction
procedure. The DNA was denatured in aqueous solution contain-
ing desferal and enzymatically hydrolysed. Chaotropic extraction
and the use of desferal are accepted methods for minimising
artifactual oxidation of the DNA. Most oxidatively induced DNA
base modifications, such as the formamide and thymine glycol
modifications, inhibit hydrolysis by nuclease P1 of the phosphoe-
ster bond 30 to the modified deoxyribonucleoside (Falcone and
Box, 1997). Consequently, these lesions appear in a nuclease P1
(plus alkaline phosphatase) hydrolysate of DNA predominately as
modified dinucleoside monophosphates; for example as in Figure
1A and B. Measuring these lesions at the dimer level has
advantages: (1) The sensitivity of liquid chromatography-tandem
mass spectrometry (LC-MS/MS) detection, using electrospray
ionisation and operating in the negative ion mode, is better for
dinucleoside monophosphates than for nucleosides (Bailey et al,
2006); (2) Isotopically labelled internal standards for quantifying
these lesions can be obtained by labelling the nucleoside 30 to the
modified nucleoside. As the inhibition of nuclease P1 by the
modified nucleoside is not absolute, it would seem that
quantification at the dimer level is problematical. However, this
difficulty is circumvented by adding the internal standard in the
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sform of an oligomer bearing the lesion and the label to the DNA
before digest. Internal standards (ZeptoMetrix Corp.) of the form
d(GpApApT
fpA*) and d(GpCpApT
gpA*) were added to the
denatured DNA sample before enzymatic digest where the asterisk
indicates a purine base
15N labelled at all positions. As modified
dinucleoside monophosphate derived from the DNA from the
sample and from the internal standard are chemically identical,
loss of product due to partial hydrolysis is accounted for in the
final quantification step. The measurement of DNA damage at the
dimer level has been described previously (Bailey et al, 2006;
Greene et al, 2007). Samples contained 100mg of DNA. The
samples were processed by HPLC before analysis by LC-MS/MS.
The eluant between peaks due to unmodified deoxyribonucleo-
sides was collected for analysis. The purpose of the HPLC step was
to remove salt and unmodified nucleosides, thus reducing the
amount of the sample injected into the mass spectrometer.
The effects of two forms of radiation commonly used to generate
ROS, namely ionising radiation and UVC, were used to treat cells.
The hydroxyl radical is the most significant ROS associated with
ionising radiation, whereas the likely active agent in the case of
UVC is singlet oxygen.
RESULTS
DNA damage induced in vitro
In vitro experiments were carried out to compare background
levels of DNA damage in WBC vs levels induced by familiar
sources of ROS. Two modalities commonly used to generate ROS
are ionising radiation and UVC. WBC resuspended in plasma from
the original blood sample were subjected to ionising radiation
(500Gy). Levels of d(P
fpA), Figure 1A, and d(T
gpA), Figure 1B,
were measured by LC-MS/MS. A typical set of LC-MS/MS elution
profiles is shown in Figure 2. Quantitative results are presented in
Table 1. A significant increase was observed for the thymine glycol
lesion with little increase in the formamide lesion. The increase in
d(T
gpA) produced in WBC exposed to 500Gy was found to be
3.46fmolmg
 1 of DNA. Taking into account all four sequences of
d(T
gpN), where N stands for a normal nucleoside, this yield can be
expressed as 3.55T
g/10
6N.
WBC were resuspended in PBS and exposed to 250Jm
 2 of
UVC. The results are included in Table 1. For this modality,
formamide damage is more significantly enhanced than thymine
glycol damage. The formamide modification has received relatively
little attention as a product of oxidative stress, probably because it
is not conveniently detected at the monomer level.
DNA damage in WBC of ovarian cancer patients and
controls
The levels of the formamide and thymine glycol modifications in
ovarian cancer patients vs controls are compared in Table 2. The
level on average of the formamide modification, d(P
fpA), is higher
in the cancer patients (6.38fmolmg
 1) than in controls
(5.56fmolmg
 1). The level on average of the thymine glycol
modification, d(T
gpA), is also higher in the cancer patients
(2.83fmolmg
 1) than in controls (2.16fmolmg
 1). The difference
statistic between the mean values of the patient and control
samples was analysed in terms of t-values. The a-values for the
formamide and thymine glycol modification, based on the
t-distribution for 32 degrees of freedom, are 0.25 and 0.15,
respectively (van Belle et al, 2004.
A principal concern in the interpretation of the results of Table 2
is a potential age factor. Figures 3 and 4 display the range and
distribution of ages for the patient and control groups. The
distributions are plotted vs the levels of d(P
fpA) and d(T
gpA),
respectively. The age distributions for cases and controls are not
identical. An ad hoc, but insightful, approach to evaluating age as a
possible confounding factor. The control data to the equation
y¼axþb, where y stands for the level of damage, d(P
fpA), and x
stands for the age of the individual in years. A least squares best fit
of the d(P
fpA) data as a function of age yielded values of
0.090fmolmg
 1 per year and 1.343fmolmg
 1 for a and b,
respectively. These values were used to calculate the expected
levels of d(P
fpA) in cancer patients based on their individual ages.
The mean value of d(P
fpA) for the 19 cancer patients was
calculated. The value of 5.57fmolmg
 1 was obtained which is
substantially the same value listed in Table 2. Thus, the relevance
of the higher measured level of d(P
fpA) in cancer patients
compared with controls is of doubtful significance. On the other
hand, the levels for d(T
gpA) appear to be more meaningful. The
least squares best fit for the control data of Figure 4 yielded values
of 0.023fmolmg
 1 per year and 1.081fmolmg
 1. The calculated
mean value of d(T
gpA) in cancer patients was 2.16fmolmg
 1 which
is significantly below the measured value of 2.83fmolmg
 1.
Other factors that may influence our results merit consideration.
Berwick and Vineis (2000) reviewed 64 studies of cancer in relation
to DNA damage and repair and tabulated the covariates considered
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Figure 1 Forms of the formamide (A) and thymine glycol (B) modifications, measured by LC-MS/MS.
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sin each study. Age, gender and smoking habits were the covariates
most frequently considered. (The next most frequent practice in
these studies was to omit consideration of cofactors altogether.)
We have already considered the age factor and, of course, all of our
study participants are women. An interesting insight came from
background information on smoking habits. Of the 19 patients, 10
were former smokers. Only one reported being a current smoker (2
cigarettes per day). Similarly, 7 of 15 women in the control group
were former smokers but none is a current smoker. Our
conclusion is that the smoking habit is on the wane. Alcohol
usage was similar in the two groups, 8 of 19 and 10 of 15 in cases
and controls, respectively. Cancer incidence among immediate
family members was also similar, 10 of 19 for cases and 8 of 15 for
controls. For women taking birth control medications, the ratios
were 8 of 19 and 9 of 15 in cases and controls, respectively.
Berwick and Vineis (2000) discuss whether an increase in DNA
damage associated with cancer may be caused by the tumour itself,
that is, reverse causation. For example, it is hypothesised that
cancer cells release ROS into the blood stream. It seems unlikely,
however, that any one reverse-causation mechanism would
account for the increase in oxidative DNA damage observed in a
wide range of malignancies (see next section). Bhatti et al (2008)
have addressed the question of reverse causation experimentally.
These investigators found no evidence of reverse causation using
the comet assay to measure DNA damage in women before and
after diagnosis.
DISCUSSION
The hypothesis that oxidative stress is a risk factor for cancer
received considerable impetus with the realisation that oxidative
stress probably originates primarily from normal metabolic
processes (Ames et al, 1992). Cells synthesise ATP and in the
process generate ROS, particularly hydrogen peroxide and super-
oxide. ROS-induced DNA damage generates mutations that
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Figure 2 LC-MS/MS elution profiles of the formamide and thymine glycol modifications obtained from the DNA of untreated WBC from a healthy
donor. The second trace in each example is from the internal standard, which serves to quantify the measurement.
Table 1 Levels of formamide and thymine glycol lesions in WBC
compared with levels in WBC exposed to 500Gy X-ray or 250Jm
 2 UVC
dP
fpAlg
 1 dT
gpAlg
 1
Samples (5), control 4.89±0.76 2.23±0.34
Samples (5), 500Gy 5.37±1 02 5.69±1.02
Samples (8), control 5.76±0.75 4.48±1.01
Samples (8), 250 Jm
 2 14.6±2.08 8.41±1.36
Values are given in femtomoles of lesion per microgram of DNA. Numbers in
parentheses indicate the number of donors; error measures are standard errors of
the mean.
Table 2 Levels of the formamide and thymine glycol modifications in
WBC of ovarian cancer patients and healthy controls
dP
fpAlg
 1 dT
gpAlg
 1
Ovarian cancer patients (19) 6.38±0.83 2.83±0.45
Controls (16) 5.56±0.86 2.16±0.38
Values are given in femtomoles of lesion per microgram of DNA. Numbers in
parentheses indicate the number of donors; error measures are standard errors of
the mean.
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spresumably contribute to tumorigenesis. Thus, oxidative stress is a
plausible global cause of cancer.
In this study two ROS-induced pyrimidine modifications of
DNA were studied, namely the formamide remnant derived from
pyrimidine bases and the thymine glycol modification of thymine
base. Both modifications are produced in cells exposed to ionising
radiation or to UVC (Bailey et al, 2006; Greene et al, 2007).
However, the damage profiles are different depending on the ROS
source, illustrating the advantage of evaluating oxidative stress
through the simultaneous measurement of more than one lesion.
LC-MS/MS technology permits the simultaneous measurement of
multiple lesions (see below).
Evidences from many laboratories have supported the observa-
tion that oxidatively induced DNA damage, as measured by the
level of 8-oxo-7,8-dihydroguanine in WBC of peripheral blood, on
average, is higher in cancer patients (see Table 3). It is helpful to
review the measurements of oxidative DNA damage in terms of
percentage increases in the level of DNA damage relative to each
laboratory’s control value. In Table 3, we have taken the liberty of
presenting data reported by other laboratories in a format
somewhat different from the original reports. This is done to
facilitate discussion and comparison with our own data. Table 3
lists the levels of the 8-oxo-7,8-dihydroguanine modification, dG
h,
measured in the DNA of WBC of cancer patients and in healthy
controls. Typically, 8-oxo-7,8-dihydroguanine data, obtained by
electrochemical or
32P-postlabeling methods, are reported in terms
of dG
h/10
6dG where dG stands for deoxyguanine. In Table 3, the
values are converted to dG
h/10
6N where N stands for normal bases.
The consistent increase in the level of dG
h in cancer patients
relative to healthy controls is strong evidence that cancer is related
to oxidative stress. On the other hand, though measurements of
dG
h/10
6N do distinguish between cancer groups and healthy
control groups, the variation in dG
h/10
6N measured among control
populations is disconcerting. The background/control levels
reported in Table 3 differ by more than two orders of magnitude.
Among sizeable healthy populations dG
h/10
6N should be a quasi-
fixed quantity. The variation is usually ascribed to artifactual
oxidation of guanine (Collins et al, 2004; ESCODD et al, 2005). An
expedient is to accept each laboratory’s determination of the
background level according to its own method and calculate the
percentage increase in the patient level. This has been done in
Table 3. The percentage increases reported for all cancer types are
fairly consistent.
Added to Table 3 are measurements from this study of the
formamide and thymine glycol modifications in patients having
ovarian cancer and in healthy female controls. For MS measure-
ments it is customary to quantify products in terms of moles per
weight of injected material, as in Table 2. For our present purpose
results have been converted into terms of dT
g/10
6N and dP
f/10
6dN.
It is interesting to note that the values for dP
f/10
6N and dT
g/10
6N
fall close to the median values reported for dG
h/10
6N.
The levels of the formamide and thymine glycol lesions are
lower in our control group compared with the patient group.
However, as noted above, it is problematical whether the increase
in the formamide modification is related to cancer. Nevertheless,
the trend is the same for the pyrimidine modifications as for
8-oxo-7,8-dihydroguanine and our results add weight to the
hypothesis that oxidative DNA damage is a contributor to the
multiple mutations occurring during tumorigenesis (Sjoblom et al,
2007; Wood et al, 2007.
It is unlikely that measurements of the formamide and thymine
glycol base modifications will be plagued by the difficulties that
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Figure 3 Range and distribution of ages of case and control participants
plotted against d(P
fpA) levels.
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Figure 4 Range and distribution of ages of case and control participants
plotted against d(T
gpA) levels.
Table 3 Oxidative DNA damage in cancer and control groups
Study group Control (n) Study group (n) D% Reference
Lung cancer, dG
h/10
6N 7.30±1.12 (48) 11.6±1.54 (46) +59 Vulimiri et al (2000)
Leukemia, dG
h/10
6N 8.52±0.55 (11) 13.6±0.72 (22) +60 Oltra et al (2001)
Colorectal cancer, dG
h/10
6N 1.91±0.13 (35) 2.74±0.23 (36) +43 Gackowski et al (2002)
Bladder cancer, dG
h/10
6N 4.36±0.19 (22) 7.52±0.58 (29) +71 Akcay et al (2003)
Breast cancer, dG
h/10
6N 121±18 (32) 278±29 (29) +128 Soliman et al (2004)
Oesophagial cancer, dG
h/10
6N 0.98±0.06 (43) 1.44±0.12 (17) +46 Breton et al (2005)
Ovarian cancer, dP
f/10
6N 5.63±0.87(15) 6.43±0.84(19) +14 This report
Ovarian cancer, dT
g/10
6N 2.16±0.38(15) 2.83±0.45(19) +31 This report
Measurements of 8-oxo-7,8-dihydroguanine , formamide and thymine glycol modifications in cancer and control groups. Values are dG
h/10
6N, dP
f/10
6No rd T
g/10
6N±s.e.m.;
numbers in parentheses indicate the number of participants.
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shave attended the measurements of 8-oxo-7,8-dihydroguanine
(Collins et al, 2004; ESCODD et al, 2005). This expectation is based
on the lower ionisation energy of the pyrimidine bases and less
likely artifactual oxidation of pyrimidine bases compared with
guanine (Halliwell, 2000; Steenken et al, 2000).
It is feasible to measure multiple DNA modifications simulta-
neously using the LC-MS/MS technology. In this connection an
additional remark may be made concerning our practice of
measuring DNA damage at the dimer level. The selectivity,
sensitivity and the ability to measure multiple modifications
simultaneously makes LC-MS/MS technology well suited for
assessing DNA damage. But to realise these advantages one must
know beforehand the molecular weights of the product of interest
and of a principal fragmentation product. By assaying at the
dinucleoside monophosphate level a predictable fragment is
always obtained from the 30 end of the molecule independent of
the nature of the modified 50 end. Thus, the second MS value can
be programmed for one of four values. It becomes feasible to
perform a comprehensive survey of a DNA digest by programming
the first MS value over a range of mass values. Using this approach
we have observed signals in the DNA from WBC due to five
modifications, all of which are more abundant than either 8-oxo-
7,8-dihydroguanine or the thymine glycol lesions. We hope to use
this broader spectrum of DNA modifications to better define the
relationship between oxidative stress and cancer risk (Wang et al,
submitted) and to clarify the role of antioxidants in the prevention
of cancer. Molecular biomarkers may provide clearer guidance on
the use of antioxidants in the prevention of cancer than is
currently available from epidemiology studies (Hercberg et al,
2006; Reid et al, 2008; Sesso et al, 2009).
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